Targeted therapy comes of age in scleroderma

Trends in Immunology

Volumn 26, Issue 11, 2005, Pages 596-602

  Denton, Christopher P ^a   Black, Carol M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN LIKE KINASE 5 INHIBITOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIOXIDANT; BOSENTAN; CALCINEURIN INHIBITOR; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HALOFUGINONE; IMATINIB; METHOTREXATE; PHOSPHODIESTERASE V INHIBITOR; PIRFENIDINE; PLATELET DERIVED GROWTH FACTOR INHIBITOR; PROBUCOL; PROLYLHYDROXYLASE INHIBITOR; PROSTACYCLIN DERIVATIVE; QUINAPRIL; RAPAMYCIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HEREDITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; LUNG FIBROSIS; MIDGUT; MYOSITIS; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

AGE FACTORS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSION; MODELS, IMMUNOLOGICAL; SCLERODERMA, SYSTEMIC;

EID: 28444493035     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2005.09.002     Document Type: Review

References (39)

1. K.M. McKown Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen Arthritis Rheum. 43 2000 1054 1061
2. D.E. Furst High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward J. Rheumatol. 31 2004 2331 2335
3. R.K. Burt The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis Bone Marrow Transplant. 34 2004 745 751
4. D. Farge EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry Ann. Rheum. Dis. 63 2004 974 981
5. M. Beon Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis Clin. Exp. Rheumatol. 22 2004 733 742
6. F.K. Tan Examination of the possible role of biologically relevant genes around FBN1 in systemic sclerosis in the Choctaw population Arthritis Rheum. 48 2003 3295 3296
7. X. Zhou Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence Arthritis Rheum. 48 2003 2585 2592
8. F.K. Tan Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations Arthritis Rheum. 44 2001 893 901
9. L.D. Siracusa A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation Genome Res. 6 1996 300 313
10. C. Feghali-Bostwick Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies Arthritis Rheum. 48 2003 1956 1963
11. H.R. Maricq Prevalence of scleroderma spectrum disorders in the general population of South Carolina Arthritis Rheum. 32 1989 998 1006
12. A. Silman An epidemiological study of scleroderma in the West Midlands Br. J. Rheumatol. 27 1988 286 290
13. R.J. Allcock A study of the prevalence of systemic sclerosis in northeast England Rheumatology (Oxford) 43 2004 596 602
14. C.C. Bunn, and C.M. Black Systemic sclerosis: an autoantibody mosaic Clin. Exp. Immunol. 117 1999 207 208
15. C.C. Bunn Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis Br. J. Rheumatol. 37 1998 15 20
16. V.J. Tormey Anti-fibrillarin antibodies in systemic sclerosis Rheumatology (Oxford) 40 2001 1157 1162
17. J. Gentiletti Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma J. Immunol. 175 2005 2418 2426
18. D.E. Furst Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial Rheumatology (Oxford) 40 2001 615 622
19. M.C. Ruzek A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease Arthritis Rheum. 50 2004 1319 1331
20. Y. Zhang Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma J. Invest. Dermatol. 121 2003 713 719
21. P.J. Christner, and S.A. Jimenez Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches Curr. Opin. Rheumatol. 16 2004 746 752
22. M. Worda In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay Arthritis Rheum. 48 2003 2605 2614
23. M.B. Kahaleh Raynaud phenomenon and the vascular disease in scleroderma Curr. Opin. Rheumatol. 16 2004 718 722
24. D. Khanna Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study Arthritis Rheum. 52 2005 592 600
25. S.J. Morton, and R.J. Powell Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma Rheumatology (Oxford) 39 2000 865 869
26. D. Shegogue, and M. Trojanowska Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway J. Biol. Chem. 279 2004 23166 23175
27. D. Farge EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry Ann. Rheum. Dis. 63 2004 974 981
28. R.J. Stratton Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma Rheumatology (Oxford) 40 2001 84 88
29. P.J. Clements High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial Arthritis Rheum. 42 1999 1194 1203
30. P.J. Clements High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned Semin. Arthritis Rheum. 33 2004 249 263
31. J.R. Seibold Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial Ann. Intern. Med. 132 2000 871 879
32. M. Pines Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma Biol. Blood Marrow Transplant. 9 2003 417 425
33. A. Azuma Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 171 2005 1040 1047
34. A.L. Negri Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents J. Nephrol. 17 2004 496 503
35. J. Varga Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts? Curr. Rheumatol. Rep. 6 2004 164 170
36. C.P. Denton Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice J. Biol. Chem. 278 2003 25109 25119
37. C.P. Denton Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor β receptor J. Biol. Chem. 280 2005 16053 16065
38. R.N. Channick Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123
39. M.D. Mayes Endothelin and endothelin receptor antagonists in systemic rheumatic disease Arthritis Rheum. 48 2003 1190 1199